Document is current
Any future updates will be listed below
-
Authors
Tsutsumi, Tsubasa https://orcid.org/0000-0001-6571-9874
Kawaguchi, Takumi
Fujii, Hideki
Kamada, Yoshihiro
Suzuki, Yuichiro
Sawada, Koji
Tatsuta, Miwa
Maeshiro, Tatsuji
Tobita, Hiroshi
Akahane, Takemi
Hasebe, Chitomi
Kawanaka, Miwa
Kessoku, Takaomi
Eguchi, Yuichiro
Syokita, Hayashi
Nakajima, Atsushi
Kamada, Tomoari
Yoshiji, Hitoshi
Sakugawa, Hiroshi
Morishita, Asahiro
Masaki, Tsutomu
Ohmura, Takumi
Watanabe, Toshio
Yoda, Yoshioki
Enomoto, Nobuyuki
Ono, Masafumi
Fuyama, Kanako
Okada, Kazufumi
Nishimoto, Naoki
Ito, Yoichi M.
Takahashi, Hirokazu
Charlton, Michael R.
Rinella, Mary E.
Sumida, Yoshio
-
Funding
Funding for this research was provided by:
Kurume University (Startup Award for Researchers with Life Events)
- License Information
-
More Information
Article History
Received: 22 January 2025
Accepted: 8 March 2025
First Online: 18 March 2025
Declaration
:
: T.K. received lecture fees from Janssen Pharmaceutical K.K., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., ASKA Pharmaceutical Co., Ltd., AbbVie GK., EA Pharma Co., Ltd. M.K. received a research grant from Fuji Rebio. A.N. received honorariums from EA Pharma Co., Ltd, Mochida Pharmaceutical Co., LTD., Kowa Company, Ltd., Taisho Pharmaceutical Co., Ltd., and Viatris; a fee from EA Pharma Co., Ltd.; and a research grant from EA Pharma Co., Ltd, Mochida Pharmaceutical Co., LTD., Kowa Company, Ltd., and Gilead Science. H.Y. received lecture fees from Otsuka Pharmaceutical Co., Ltd., Asuka Pharmaceutical Co., Ltd., Gilead Sciences, Novel Pharmaceutical, Taisho Pharmaceutical Co., Ltd., and AbbVie Inc. H.T. received lecture fees from Novonordisk, Kowa Company, Ltd., and Taisho Pharmaceutical Co., Ltd., and a fee for writing from an undisclosed company. M.E.R. provides scientific consulting for Akero, 89Bio, Boehringer Ingelheim, Intercept Pharmaceuticals, Histoindex, Madrigal, NGM Biopharmaceuticals, Novo Nordisk, Eli Lilly, Sagimet Biosciences, Sonic Incytes, Cytodyn, and GSK and serves on the scientific executive boards of Akero, Madrigal, and Novo Nordisk. M.R.C. is employed by Madrigal and previously provided scientific consulting for Novo Nordisk, 89Bio, Northsea, Merck, Akero, Cytodyn, Pfizer, Aligos, Sagimet, and Eli Lilly. Y.Su. received a research grant from an undisclosed company and scholarship grants from Takeda and Sysmex. The other authors have no conflicts of interest relevant to this publication.
